These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29882448)

  • 61. Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.
    Musunuru HB; Quon H; Davidson M; Cheung P; Zhang L; D'Alimonte L; Deabreu A; Mamedov A; Loblaw A
    Radiother Oncol; 2016 Jan; 118(1):112-7. PubMed ID: 26796591
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
    Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
    Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.
    Hummel S; Simpson EL; Hemingway P; Stevenson MD; Rees A
    Health Technol Assess; 2010 Oct; 14(47):1-108, iii-iv. PubMed ID: 21029717
    [TBL] [Abstract][Full Text] [Related]  

  • 65. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
    Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
    Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer.
    Lieng H; Pintilie M; Bayley A; Berlin A; Bristow R; Chung P; Gospodarowicz M; Huang R; Ménard C; Warde P; Catton C
    Radiother Oncol; 2017 Jan; 122(1):93-98. PubMed ID: 27838147
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of Treatment-Related Toxicity With Hypofractionated or Conventionally Fractionated Radiation Therapy for Prostate Cancer: A National Population-Based Study.
    Sujenthiran A; Parry M; Nossiter J; Berry B; Cathcart PJ; Clarke NW; Payne H; van der Meulen J; Aggarwal A
    Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):501-508. PubMed ID: 32143901
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial.
    Yeoh EE; Holloway RH; Fraser RJ; Botten RJ; Di Matteo AC; Butters J; Weerasinghe S; Abeysinghe P
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1072-83. PubMed ID: 16965866
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Toxicity outcome after three-dimensional conformal radiotherapy for early stage prostatic cancer.
    Kurtman C
    Radiat Med; 2001; 19(2):89-92. PubMed ID: 11383648
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Toxicity associated with postoperative radiation therapy for prostate cancer.
    Iyengar P; Levy LB; Choi S; Lee AK; Kuban DA
    Am J Clin Oncol; 2011 Dec; 34(6):611-8. PubMed ID: 21150565
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical comparative study of dose-volume and equivalent uniform dose based predictions in post radiotherapy acute complications.
    Boulé TP; Gallardo Fuentes MI; Roselló JV; Arrans Lara R; Torrecilla JL; Plaza AL
    Acta Oncol; 2009; 48(7):1044-53. PubMed ID: 19575313
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy.
    Mazzola R; Fersino S; Fiorentino A; Ricchetti F; Giaj Levra N; Di Paola G; Sicignano G; Naccarato S; Ruggieri R; Alongi F
    Clin Transl Oncol; 2016 Mar; 18(3):317-21. PubMed ID: 26250766
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A systematic review of hypofractionation for primary management of prostate cancer.
    Koontz BF; Bossi A; Cozzarini C; Wiegel T; D'Amico A
    Eur Urol; 2015 Oct; 68(4):683-91. PubMed ID: 25171903
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized trial comparing bladder volume consistency during fractionated prostate radiation therapy.
    Mullaney LM; O'Shea E; Dunne MT; Finn MA; Thirion PG; Cleary LA; McGarry M; O'Neill L; Armstrong JG
    Pract Radiat Oncol; 2014; 4(5):e203-e212. PubMed ID: 25194106
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Early toxicity of hypofractionated radiotherapy for prostate cancer.
    Krupa P; Ticha H; Kazda T; Dymackova R; Zitterbartova J; Odlozilikova A; Kominek L; Bobek L; Kudlacek A; Slampa P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Sep; 160(3):435-41. PubMed ID: 26948031
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
    Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
    Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.